Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
Researchers found early-life antibiotic use was linked to increased risk of asthma and eczema, but not most other immune diseases, after adjusting for familial factors.
A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.